SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19

J Endocrinol Invest. 2020 Oct;43(10):1527-1528. doi: 10.1007/s40618-020-01366-7. Epub 2020 Jul 19.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage
  • Antibodies / blood
  • Antithyroid Agents / administration & dosage
  • Betacoronavirus / isolation & purification
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques / methods
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / diagnosis
  • Coronavirus Infections* / immunology
  • Coronavirus Infections* / physiopathology
  • Female
  • Graves Disease* / blood
  • Graves Disease* / etiology
  • Graves Disease* / physiopathology
  • Graves Disease* / therapy
  • Humans
  • Lung / diagnostic imaging
  • Methimazole / administration & dosage*
  • Middle Aged
  • Pandemics*
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / etiology
  • Pneumonia, Viral* / immunology
  • Pneumonia, Viral* / physiopathology
  • Propranolol / administration & dosage*
  • Receptors, Thyrotropin / immunology*
  • SARS-CoV-2
  • Thyroglobulin / immunology*
  • Thyroid Function Tests / methods
  • Treatment Outcome
  • Ultrasonography / methods

Substances

  • Adrenergic beta-Antagonists
  • Antibodies
  • Antithyroid Agents
  • Receptors, Thyrotropin
  • Methimazole
  • Thyroglobulin
  • Propranolol